hotspot -WSS

hotspot

author：leisure time 2025-10-01 04:32:59 - browse：4544

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Boston competes with Raleigh

WSS

How generative AI ratchets up security threats for health systems

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Doulas covered by Medicaid under New York's new plan

GSK to buy asthma

How generative AI ratchets up security threats for health systems

Pancreatic cancer early detection could be helped by AI

entertainment

hotspot

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: live from JPM 2024

DIEP, the 'gold standard' of breast reconstruction, is under threat

New clues to why women have higher risk of autoimmune disorders

State Dept. review finds Biden bears some blame for Afghanistan failures

Syphilis numbers in the United States reach record heights

Virginia high school admissions case could be legal follow

Boston competes with Raleigh

Anesthesiologist group: stop taking Ozempic before surgery

Biotech reporter’s notebook: A sunnier mood at JPM 2024

hotspot

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Medicare drug price negotiation legal challenge met with skepticism

Philips to halt sales of sleep apnea machines in U.S.

Health and fitness trackers are measuring the wrong things

Designating disabled people as health disparity population is crucial

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

explore

leisure time

entertainment

hotspot